| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Sep 2, 2021 | Roche schizophrenia drug that failed PhIII gets a new life in rare disorder as OrbiMed leads $90M for startup | Until a few years ago, GlyT1, a glycine transporter, seemed like a promising target for an add-on therapy to treat negative symptoms of schizophrenia.
But scientists were thrusted back to the drawing board in 2014, when Roch... |
| Jul 19, 2021 | ‘Drug peddler’ arrested in Kolkata with heroin valued at Rs 26 crore | A 36-year-old man was arrested with 5.177 kg of heroin worth Rs 25.8 crore on E M Bypass in Kolkata, police said on Sunday.
Acting on a tip-off, a team of the Kolkata’s Special Task Force (STF) arrested accused Tapas Ray, alleged to be a dr... |
| May 7, 2021 | China’s CCT Fund leads $80m funding in Canadian drug maker Virogin Biotech | Premium
Virogin Biotech, a Vancouver-based company that specialises in oncology drugs and treatment, has secured a corpus of $80 million in a Series D1 round of financing, according to a statement.
Continue reading this story with a subscri... |
| Apr 12, 2021 | Lightspeed, Greater Bay Area Fund Pour USD100 Million Into Drug AI Startup StoneWise | (Yicai Global) April 12 -- StoneWise Technology, a Chinese firm whose artificial intelligence platform helps companies develop new drugs, has completed its Series B and B+ financing rounds, totaling USD100 million.
The Series B+ round was j... |
| Apr 9, 2021 | HK-based buyout firm Baring to invest $100m in Chinese drug maker Hutchmed | Hong Kong-based buyout firm Baring Private Equity Asia has agreed to purchase $100 million worth of shares in Hutchison China MediTech (Hutchmed), a US- and London-listed, commercial-stage, biopharmaceutical firm that aims to treat cancer a... |
| Mar 17, 2021 | China Digest: Drug maker MingMed closes $60m; Changyang Tech raises nearly $31m | Chinese pharma products developer MingMed has garnered $60 million in a Series A round, while industrial Internet security solutions provider Changyang Tech has raised nearly 200 million yuan ($30.8 million) in a Series D round. Pharmaceuti... |
| Mar 17, 2021 | China Digest: Drug maker MingMed closes $60m; Changyang Tech raises nearly $31m | Premium
Chinese pharma products developer MingMed has garnered $60 million in a Series A round, while industrial Internet security solutions provider Changyang Tech has raised nearly 200 million yuan ($30.8 million) in a Series D round.
Con... |
| Dec 11, 2020 | Chinese drug maker SciNeuro Pharma raises $100m co-led by LAV, Arch Venture Partners | SciNeuro Pharmaceuticals, a Chinese manufacturer of drugs for central nervous system (CNS) diseases, said that it has garnered $100 million in a Series A round funding jointly led by Lilly Asia Ventures (LAV) and Arch Venture Partners.
LAV ... |
| Nov 26, 2020 | Chinese cancer drug developer Biostar closes $135m pre-IPO round | Beijing Biostar Technologies, a Chinese developer of anti-tumour, small-molecule chemical drugs, announced on Thursday the completion of a Series E round at 890 million yuan (about $135 million).
The Series E round, which is also the firm’s... |
| Oct 20, 2020 | On-demand drug delivery firm Dingdang Kuaiyao raises USD 150 million in Series B+ from SoftBank, others | Beijing-based on-demand medicine retailer Dingdang Kuaiyao has closed its Series B+ round, raising RMB 1 billion (USD 150 million) from investors including Taikang Asset, Haier Biomedical, and Beijing Zhongguancun Longmen Investment Company... |
| Sep 22, 2020 | News briefing: Tiny Vaccinex's drug flops in PhII Huntington's trial, stock craters; Siolta nabs $30M Series B to develop microbiome drug | Siolta Therapeutics, a microbiome company targeting allergic diseases, raked in a $30 million Series B to develop its lead candidate, STMC-103H. The drug, which has been FDA fast-tracked, is headed for proof-of-concept... |
| Sep 21, 2020 | Roche looks to genetic modifiers for new drug targets, teaming up with Dutch biotech in $375M deal | Roche is gambling on a new way of discovering drug targets and, ultimately, promising to infuse more than $375 million into a small biotech if all goes well.
A spinout of the Netherlands Cancer Institute and Oxford Univer... |
| Aug 24, 2020 | HK-based drug R&D platform Xuanzhu Biopharmaceutical nets $116m | Premium
Xuanzhu Biopharmaceutical, an innovative drug research and development subsidiary of Hong Kong-listed Sihuan Pharmaceutical Holdings Group, has completed an 800-million-yuan ($116 million) Series A round of equity financing led by C... |
| Jul 28, 2020 | AbbVie backs an Italian startup focused on autoimmune diseases; BioTheryX advances AML drug with $35M D round | Graziano Seghezzi Sofinnova
Italy’s Enthera Pharmaceuticals has grabbed a €28 million launch round to back its work on, laying bragging rights to the largest A round ever for an Italian biotech.
The company is using “nontradi... |
| Jun 5, 2020 | Alzheimer's drug developer scores $85M | Athira Pharma, a developer of regenerative therapies designed to restore brain function, has raised $85 million in Series B financing led by Perceptive Advisors. RTW Investments, Viking Global Investors, Franklin Templeton, Logos Capital, R... |
| Jun 2, 2020 | Pfizer to invest up to US$500 million in public drug developers | REUTERS: Pfizer Inc said on Tuesday it will invest up to US$500 million into publicly traded drug developers to fund their treatment candidates and provide access to the U.S. drugmaker's scientific expertise.
Pfizer said it will make non-co... |
| May 27, 2020 | AI drug developer Exscientia raises $60M | Biotech startup Exscientia has raised $60 million in a Series C led by Novo Holdings. Existing investors Evotec, Bristol Myers Squibb, and GT Healthcare Capital also took part in the round. Founded in 2012, the Oxford-based company uses AI ... |
| Nov 5, 2019 | Steve Kafka joins Section 32 as managing partner; Takeda auctions off $660M drug portfolio in bid to reduce post-Shire M&A debt load | Steven Kafka
→ Former Thrive CEO and partner at Third Rock Ventures, Steve Kafka, has hopped aboard Section 32 as a managing partner. Within his new role, Kafka “will focus on supporting and expanding the firm’s investment... |
| Oct 28, 2019 | Chinese drug developer Kintor raises $45m led by state-backed FTZ Fund | Premium
Kintor Pharmaceutical Limited, which specializes in the research and development of prostate, breast and liver cancer drugs, has raised $45 million in a new funding round led by Shanghai Free Trade Zoon Equity Fund (FTZ Fund).
Conti... |
| Jun 5, 2019 | The UZH Life Sciences Fund investS CHF1M in an anti-obesity drug | |
| Apr 2, 2019 | Laser-activated eye cancer drug developer Aura Biosciences scores $40M in Medicxi-led round | Building on the work of NCI scientist John Schiller — who illustrated virus-like particles modeled on the human papillomavirus (HPV) tend to ignore normal epithelium and make a beeline for solid tumors and metastases —... |
| Dec 13, 2018 | A drug that was once inexpensive gets a new price tag: $375,000 | An old, formerly inexpensive drug called Firdapse was just slapped with a steep new price tag: $375,000.
The Food and Drug Administration approved Firdapse late last month to treat a rare, neuromuscular disorder called Lambert-Eaton myasthe... |
| Aug 17, 2018 | China Digest: Minsheng leads Thunder Stone round; CMVI invests $12.7m in UK drug firm Blueberry | Premium
China Minsheng Investment Group has led a RMB200 million ($29 million) series B round in karaoke provider Thunder Stone Technology while China Medical Venture Investment (CMVI) has invested $12.7 million in UK-based drug company Blu... |
| Aug 7, 2018 | Mining real world data for drug development insights, Woodford-backed AI firm seeks $77M London IPO | Putting the words “artificial intelligence” near drug development these days is a sure way to generate buzz. But can it support a $77 million (£60 million) IPO haul in the UK? Former government minister and biotech entre... |
| Jul 17, 2018 | 6 Dimensions backs Lyvgen's $30M B round; Novartis hands off global rights to IL-2 drug | → Shanghai’s immuno-oncology drugmaker Lyvgen Biopharma has scored a $30 million B round led by one of China’s most active biotech VCs — 6 Dimensions Capital. Joining the round are new investors Winfair Global and Runl... |
| Jun 27, 2018 | Neon joins the biotech IPO fiesta on Nasdaq, bagging $100M in the latest display of enthusiasm for drug developers | Neon Therapeutics just barely made it into the big H1 group of biotech IPOs that’s landed so far this year.
Hopes of helping open a new chapter in cancer therapy with their brand of highly personalized neoantigen vaccines —... |
| Nov 21, 2017 | Jeff Capello joins Biogen as CFO; Tesaro enters $500M loan agreement; Palatin licenses female libido drug to Korea's Kwangdon | Jeff Capello
→ Biogen has recruited Jeff Capello as CFO and executive vice president, filling the position a few months after losing Paul Clancy to Alexion. Capello, whose slate of previous employers spans Ortho Clin... |
| Nov 16, 2017 | X4, nearing late-phase trials of ex-Sanofi drug, raises $27M
W h i t e p a p e r
Weighing the Costs: | X4 Pharmaceuticals has raised $27 million to advance a CXCR4 inhibitor it picked up from Sanofi. The series B equips X4 to move deeper into the clinic on two fronts, with phase 2 and 3 trials in cancers and rare diseases on the horizon.
Spo... |
| Oct 31, 2017 | Online drug marketplace NetMeds raises $14 mn from Tanncam, Sistema | Online pharmacy NetMeds Marketplace Pvt. Ltd has raised $14 million (Rs 90 crore) in a new funding round led by Tanncam Investment, a Cambodian investment holding company, and Sistema Asia Fund, the venture capital fund of Russian conglomer... |
| Jul 31, 2017 | Big data analysis for drug R&D gets $10M donation from Facebook cofounder and pediatrician wife | Led by Dr. Atul Butte, ICHS seeks to use big data to help identify drugs that can be repurposed and which ones will be able to provide better outcomes. It also addresses privacy and security issues for making data from electronic medical re... |
| Feb 13, 2017 | Indy-founded drug firm lands nearly $23M to fight rare disease | |
| Jun 23, 2016 | Oncology Drug Startup Hengrui Therapeutics Raises $100M | Hengrui Therapeutics Inc., a Princeton, N.J.-based oncology drug startup, raised $100m in funding.
The backer was HR Bio Holdings Limited, a joint venture between Jiangsu Hengrui Medicine Co. Ltd.* and an undisclosed blue chip investment fi... |
| Nov 26, 2015 | Hyperlocal drug delivery startup Pluss raises $1M | Pluss, a hyperlocal delivery startup for medicines and healthcare products, has raised $1 million (Rs 6.65 crore) in pre-Series A funding from IDG Ventures India, Singapore's M&S Partners and US-based Powerhouse Ventures.
The Gurgaon-ba... |
| Oct 28, 2013 | Actis invests $48M in drug manufacturer Symbiotec Pharmalab | Private equity firm Actis has invested $48 million (around Rs 295 crore) to pick a significant stake in Indore-based active pharmaceutical ingredients (API) company Symbiotec Pharmalab Ltd. According to the company’s statement, Symbiotec is... |
| Mar 28, 2013 | Molecular analysis instrument producer for drug analysis raises $1.3M to boost European market reach | The technology behind Spectra Analysis Instruments’ DiscovIR system was born at Argonne National Lab at the University of Chicago, Giansanti said, and the company has made further patentable developments.
Among the trends that present oppor... |
| Nov 14, 2012 | Drug developer advancing Phase 2 drug for Lou Gehrig’s disease raises $15M | Product: Its lead product is dexpramipexole for amyotrophic lateral sclerosis or Lou Gehrig’s disease and is being developed with Biogen. It is designed to protect stressed neurons and other cell types from dying, according to its website. ... |
| Aug 14, 2012 | Orphan drug firm with potential first treatment for HIBM raises $15 million | Solution/product: Ultragenyx is developing a sialic acid replacement therapy for treatment of the rare, progressive neuromuscular disease hereditary inclusion body myopathy. The disease is caused by a deficiency in sialic acid that causes m... |
| Jul 24, 2012 | RNAi drug delivery company secures $1.6M for endosomal escape technology | City, State: Seattle, Washington
Solution/Product: PhaseRx’s mechanism uses synthetic polymers to deliver RNAi drugs, which companies are developing to silence disease-causing genes, across cell membrane and into the cytoplasm by mediating ... |
| Jul 6, 2012 | Drug reformulation company raising $2 million to advance cancer treatment | Thar’s strategy reflects the broader efforts by larger pharmaceutical companies to find new ways to add to their extend patent exclusivity. In addition to reformulation, companies have adopted other strategies such as new drug combinations ... |
| Jul 3, 2012 | Pharma reviving Boehringer’s female sexual dysfunction drug gets $17.6M | Sprout is working with flibanserin, a compound it acquired from Boehringer Ingelheim, which originally developed the drug to treat depression before discovering its potential to treat HSDD. Sprout snatched up the compound after an U.S. Food... |
| Feb 21, 2012 | Non-Hodgkin’s lymphoma drug company gets $15M venture backing | Ceptaris Pharmaceuticals in Malvern, Pennsylvania has received $7.5 million and will be given access to another $7.5 million if the NDA gets approved by U.S. regulators.
Its primary venture capital investors are Osage Ventures, Aperture Ven... |
| Feb 9, 2012 | Celgene invests $15 million for closer collaboration with cancer drug co. | Walter C. Ogier, Acetylon’s president and chief executive officer, said in a company statement:
“The potential synergistic combination of Celgene’s class-leading myeloma drug, Revlimid, with Acetylon’s selective HDAC6 inhibitor, ACY-1215, i... |
| Jan 17, 2011 | Zephyr Peacock To Invest $5M In Aizant Drug Research | Zephyr Peacock India, a mid-market private equity fund investing in small and medium enterprises, is putting in $5 million for a minority stake in Hyderabad-based Aizant Drug Research Solutions Pvt. Ltd (Aizant), an integrated drug developm... |
| Jan 7, 2011 | Drug reformulation firm Thar Pharmaceuticals raises $4.3M | The company will use the Series A to get it through Phase 2 trials of its lead product candidate, a cancer drug that Houck declined to provide any further details on.
The Pittsburgh-based company’s business model involves reformulating on-t... |
| Jul 21, 2010 | Drug reformulation firm iCeutica raises $2.6M | In 2009, iCeutica released a terse statement saying that it had signed its first “Big Pharma” client, though it didn’t identify the company.
In 2005, the company announced that it had landed a Series A round of financing, but didn’t say how... |
| Oct 23, 2008 | Drug Developer Phenomix Nixes $86.25M IPO | Share Share on Facebook Share on Twitter LinkedIn Email Reprints
San Diego-based biotech firm Phenomix has withdrawn its plans to raise $86.25 million in an initial public offering—more evidence that even mature biotechs ready for late-stag... |
| Jun 19, 2007 | Drug inhalation company MAP Pharma files for $86M IPO | MAP Pharmaceuticals, a Mountain View, Calif., developer of reformulated drugs for inhalation, has filed to raise up to $86 million in an initial public offering.
See VentureBeat LifeSciences story here.
VentureBeat VentureBeat's mission is ... |
| This Cambridge AI drug startup raises £33M to tackle ‘undruggable’ diseases | The Cambridge, UK-based AI drug startup – PhoreMost has recently secured £33m funding in oversubscribed Series B funding round. The funding will push the PLK1 program for the treatment of brain cancer in the clinic within 18 months.
The rou... |
| Janux Therapeutics Announces $56 Million Series A to Advance Novel Cancer Drug Candidates Using T Cell Engager (TRACTr) Technology | SAN DIEGO--(BUSINESS WIRE)--Mar 3, 2021--
Janux Therapeutics today announced the close of a $56 million Series A financing led by Avalon Ventures and joined by new investors, OrbiMed and RA Capital Management, as well as existing investors,... |